Access Delayed, Access Denied: Waiting for New Medicines in Canada 2008

Printer-friendly version

This is the Fraser Institute's second annual report on the amount of time patients must wait to access new medicines in Canada. The purpose of this report is: (1) to draw attention to the impact that Canadian public policies and institutions have on lengthening the time it takes for patients to access newly invented, patented prescription drugs; (2) to compare consumer access to new drugs under government drug insurance programs with access under private sector drug insurance in Canada; and (3) to offer alternative policy options that could improve access to new drugs in Canada.


More from this study

Subscribe to the Fraser Institute

Get the latest news from the Fraser Institute on the latest research studies, news and events.